Compare Moderna, Inc. (MRNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Koninklijke Philips NV — how do they compare? Moderna, Inc. trades at $60.53 (market cap $24.18B), while Koninklijke Philips NV trades at $26.99 (market cap $26.58B). The key difference: Moderna, Inc. and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PHG | |
|---|---|---|
Market Cap | $24.18B | $26.58B |
Sector | Health | Health |
52-Week High | $81.80 | $32.91 |
52-Week Low | $22.36 | $25.02 |
Enterprise Value | $20.33B | $33.13B |
Dividend Yield | — | 3.75% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
